2026 Q2 - tulosraportti
89 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,40%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 400 | ||
| 5 237 | ||
| 6 000 | ||
| 6 000 | ||
| 6 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
4 t sittenReady for a big drop on Wednesday?
If you have shorted you are in for a proper financial slap on the wrist🤷♂️ on the other hand 5 stars for today's most stupid post 🙄
·5 t sittenFrom November 1, 2026, Blue Cross and Blue Shield in five US states will introduce a voluntary subsidy scheme to make weight loss medication more affordable. Fixed copayment: Eligible patients can get a copayment of 150 USD for up to 30 days of treatment. Included drugs: Novo Nordisk's Wegovy (both injection and pill) as well as Eli Lilly's Zepbound and Foundayo. Area: Illinois, Montana, New Mexico, Oklahoma and Texas. Administration: The scheme is administered by Prime Therapeutics and applies at pharmacies that are part of the network, as well as by mail order. Insurance benefit: The copayment counts toward the patient's deductible and maximum annual out-of-pocket expenses. Important limitation: The scheme is voluntary for employer-sponsored, self-funded health insurances. This means that not all policyholders automatically get access to it. Significance for Novo Nordisk: The initiative can increase accessibility and demand for Wegovy in the US by reducing patient copayments. This can be positive for Novo Nordisk's US sales and competitive position in the obesity treatment market.- ·6 t sittenThe Wegovy pill is expected to be launched in Spain in early November 2026 Novo Nordisk's Wegovy oral treatment is expected to become available in Spain in early November 2026, according to healthcare provider ZAVA. The daily treatment with semaglutide in tablet form has already received European regulatory approval and has been included in Spain's official medicinal product database. The preparation is available in tablet strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg. The Spanish Ministry of Health has further confirmed that the treatment will not be covered by public medicinal reimbursement. The expected launch will mean that Novo Nordisk is expanding its oral obesity treatment to yet another major European market. However, the company has not yet confirmed an official launch date or a local price in Spain.
·8 t sittenI have summarized this week's most important Novo news in this post: https://x.com/investseekers/status/2116925198037360901?a=cABivj0XLJwVLdUOItc&s=20
If one is to make a comparison between Eli Lilly and Novo, one can say that Eli Lilly has the upper hand on the injection-based agents, and that Novo, with disappointing sales of Eli Lilly's Foundayo, has the upper hand on the tablet market- ·18 t sittenNovo Nordisk is expected to launch the oral Wegovy treatment in Poland on Monday, November 2, 2026 – the same day as in France. This is according to the Polish pharmacy platform GdziePoLek, citing the manufacturer. Poland is an attractive market for obesity treatment: Approximately 21.8% of the adult population in Poland lives with obesity according to WHO (2024). The Polish market for GLP-1 preparations and related treatments for diabetes and obesity reached a turnover of 3.39 billion PLN in 2025 compared to 1.79 billion PLN in 2024. This corresponds to a growth of around 89%. Semaglutide preparations accounted for 1.45 billion PLN, corresponding to approximately 43% of the market's total value. Eli Lilly's Mounjaro had a turnover of 1.6 billion PLN in Poland in 2025. The launch of Wegovy as a daily tablet follows the introduction of Wegovy 7.2 mg as a weekly injection treatment in Poland on September 21, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
89 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,40%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenReady for a big drop on Wednesday?If you have shorted you are in for a proper financial slap on the wrist🤷♂️ on the other hand 5 stars for today's most stupid post 🙄
- ·5 t sittenFrom November 1, 2026, Blue Cross and Blue Shield in five US states will introduce a voluntary subsidy scheme to make weight loss medication more affordable. Fixed copayment: Eligible patients can get a copayment of 150 USD for up to 30 days of treatment. Included drugs: Novo Nordisk's Wegovy (both injection and pill) as well as Eli Lilly's Zepbound and Foundayo. Area: Illinois, Montana, New Mexico, Oklahoma and Texas. Administration: The scheme is administered by Prime Therapeutics and applies at pharmacies that are part of the network, as well as by mail order. Insurance benefit: The copayment counts toward the patient's deductible and maximum annual out-of-pocket expenses. Important limitation: The scheme is voluntary for employer-sponsored, self-funded health insurances. This means that not all policyholders automatically get access to it. Significance for Novo Nordisk: The initiative can increase accessibility and demand for Wegovy in the US by reducing patient copayments. This can be positive for Novo Nordisk's US sales and competitive position in the obesity treatment market.
- ·6 t sittenThe Wegovy pill is expected to be launched in Spain in early November 2026 Novo Nordisk's Wegovy oral treatment is expected to become available in Spain in early November 2026, according to healthcare provider ZAVA. The daily treatment with semaglutide in tablet form has already received European regulatory approval and has been included in Spain's official medicinal product database. The preparation is available in tablet strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg. The Spanish Ministry of Health has further confirmed that the treatment will not be covered by public medicinal reimbursement. The expected launch will mean that Novo Nordisk is expanding its oral obesity treatment to yet another major European market. However, the company has not yet confirmed an official launch date or a local price in Spain.
- ·8 t sittenI have summarized this week's most important Novo news in this post: https://x.com/investseekers/status/2116925198037360901?a=cABivj0XLJwVLdUOItc&s=20If one is to make a comparison between Eli Lilly and Novo, one can say that Eli Lilly has the upper hand on the injection-based agents, and that Novo, with disappointing sales of Eli Lilly's Foundayo, has the upper hand on the tablet market
- ·18 t sittenNovo Nordisk is expected to launch the oral Wegovy treatment in Poland on Monday, November 2, 2026 – the same day as in France. This is according to the Polish pharmacy platform GdziePoLek, citing the manufacturer. Poland is an attractive market for obesity treatment: Approximately 21.8% of the adult population in Poland lives with obesity according to WHO (2024). The Polish market for GLP-1 preparations and related treatments for diabetes and obesity reached a turnover of 3.39 billion PLN in 2025 compared to 1.79 billion PLN in 2024. This corresponds to a growth of around 89%. Semaglutide preparations accounted for 1.45 billion PLN, corresponding to approximately 43% of the market's total value. Eli Lilly's Mounjaro had a turnover of 1.6 billion PLN in Poland in 2025. The launch of Wegovy as a daily tablet follows the introduction of Wegovy 7.2 mg as a weekly injection treatment in Poland on September 21, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 400 | ||
| 5 237 | ||
| 6 000 | ||
| 6 000 | ||
| 6 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
89 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,40%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenReady for a big drop on Wednesday?If you have shorted you are in for a proper financial slap on the wrist🤷♂️ on the other hand 5 stars for today's most stupid post 🙄
- ·5 t sittenFrom November 1, 2026, Blue Cross and Blue Shield in five US states will introduce a voluntary subsidy scheme to make weight loss medication more affordable. Fixed copayment: Eligible patients can get a copayment of 150 USD for up to 30 days of treatment. Included drugs: Novo Nordisk's Wegovy (both injection and pill) as well as Eli Lilly's Zepbound and Foundayo. Area: Illinois, Montana, New Mexico, Oklahoma and Texas. Administration: The scheme is administered by Prime Therapeutics and applies at pharmacies that are part of the network, as well as by mail order. Insurance benefit: The copayment counts toward the patient's deductible and maximum annual out-of-pocket expenses. Important limitation: The scheme is voluntary for employer-sponsored, self-funded health insurances. This means that not all policyholders automatically get access to it. Significance for Novo Nordisk: The initiative can increase accessibility and demand for Wegovy in the US by reducing patient copayments. This can be positive for Novo Nordisk's US sales and competitive position in the obesity treatment market.
- ·6 t sittenThe Wegovy pill is expected to be launched in Spain in early November 2026 Novo Nordisk's Wegovy oral treatment is expected to become available in Spain in early November 2026, according to healthcare provider ZAVA. The daily treatment with semaglutide in tablet form has already received European regulatory approval and has been included in Spain's official medicinal product database. The preparation is available in tablet strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg. The Spanish Ministry of Health has further confirmed that the treatment will not be covered by public medicinal reimbursement. The expected launch will mean that Novo Nordisk is expanding its oral obesity treatment to yet another major European market. However, the company has not yet confirmed an official launch date or a local price in Spain.
- ·8 t sittenI have summarized this week's most important Novo news in this post: https://x.com/investseekers/status/2116925198037360901?a=cABivj0XLJwVLdUOItc&s=20If one is to make a comparison between Eli Lilly and Novo, one can say that Eli Lilly has the upper hand on the injection-based agents, and that Novo, with disappointing sales of Eli Lilly's Foundayo, has the upper hand on the tablet market
- ·18 t sittenNovo Nordisk is expected to launch the oral Wegovy treatment in Poland on Monday, November 2, 2026 – the same day as in France. This is according to the Polish pharmacy platform GdziePoLek, citing the manufacturer. Poland is an attractive market for obesity treatment: Approximately 21.8% of the adult population in Poland lives with obesity according to WHO (2024). The Polish market for GLP-1 preparations and related treatments for diabetes and obesity reached a turnover of 3.39 billion PLN in 2025 compared to 1.79 billion PLN in 2024. This corresponds to a growth of around 89%. Semaglutide preparations accounted for 1.45 billion PLN, corresponding to approximately 43% of the market's total value. Eli Lilly's Mounjaro had a turnover of 1.6 billion PLN in Poland in 2025. The launch of Wegovy as a daily tablet follows the introduction of Wegovy 7.2 mg as a weekly injection treatment in Poland on September 21, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 400 | ||
| 5 237 | ||
| 6 000 | ||
| 6 000 | ||
| 6 000 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt